GASTROINTESTINAL CANCERS

REFERENCES

• Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care versus best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658–64
   PubMed Web of Science ®Google Scholar
• Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–345
   PubMed Web of Science ®Google Scholar
• Berlin J., Van Cutsem E., Peeters M., Hecht J. R., Wolf M., Amado R., Meropol N J. Safety and efficacy of panitumumab monotherapy in the treatment of metastatic colorectal cancer (MCRC)—summary of results across clinical studies. Ann Oncol 2006; 17: x114, (suppl9)
   Web of Science ®Google Scholar
• Hecht J. R., Peeters M., Van Cutsem E., et al. Safety and tolerability of panitumumab, a fully human monoclonal antibody (MAB), in patients (PTS) with metastatic colorectal cancer (MCRC). Ann Oncol 2006; 17: x124, (suppl9)
   Web of Science ®Google Scholar
• Berlin J., Van Cutsem E., Peeters M., Hecht J. R., Ruiz R., Wolf M., Amado R. G., Meropol N. J. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): A pooled analysis of five clinical trials. J Clin Oncol 2007; 25: 196s, (suppl)
   PubMedGoogle Scholar
• Berlin J., Posey J., Tchekmedyian S., et al. Panitumumab with Irinotecan, Leucovorin, and 5-Fluorouracil (IFL or FOLFIRI) for First-Line Treatment of Metastatic Colorectal Cancer. Clin Colorect Cancer 2007; 6: 427–432
   PubMed Web of Science ®Google Scholar
• Hecht J. R., Chidiak T., Mitchell E. An interim analysis of efficacy and safety from a randomized controlled trial of Panitumumab with chemotherapy plus Bevacizumab (Bev) for metastatic colorectal cancer (mCRC). Proc World Congress on GI Cancers 2007
   Google Scholar
• Serra I., Calvo A., Sharp A. Gallbladder cancer. Rev. Med Chil 1987; 115: 706–708
   PubMed Web of Science ®Google Scholar
• Falkson G., MacIntyre J. M., Moertel C. G. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 1984; 54: 965–969
   PubMed Web of Science ®Google Scholar
• Taal B. G., Audisio R. A., Bleiberg H., et al. Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group study. Ann Oncol 1993; 4: 607–609
   PubMed Web of Science ®Google Scholar
• Jones D. V., Jr., Lozano R., Hoque A., et al. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 1996; 14(8)2306–2310
   PubMed Web of Science ®Google Scholar
• Fishkin P., Alberts S., Mahoney M., et al. Irinotecan (CPT-11) in Patients with advanced Gallbladder (GB) Carcinoma: A North Central Cancer Treatment Group (NCCTG) Phase II Study. Proc Am Soc Clin Oncol 2001; 20, abstract 618
   Google Scholar
• Harvey J. H., Smith F. P., Schein P. S. 5-Fluorouracil, mitomycin, doxorubicin (FAM) in carcinoma of biliary tract. J Clin Oncol 1984; 2: 1245–1248
   PubMed Web of Science ®Google Scholar
• Takada T., Kato H., Matsushiro T., et al. Comparison of 5-fluorouracil, doxorubicin and mitomycin-C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 1994; 51: 396–400
   PubMed Web of Science ®Google Scholar
• Gallardo J., Rubio B., Fodor M., et al. A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 2001; 12: 1403–1406
   PubMed Web of Science ®Google Scholar
• Gallardo J., Rubio B., Fodor M., et al. Gemcitabine in gallbladder cancer: Clinical benefit assessment. Proc Am Soc Clin Oncol 2002; 21, abstract 2305
   Google Scholar
• Reyes-Vidal J., Gallardo J., Yáñez E., et al. Gemcitabine and cisplatin in the treatment of patients with unresectable or metastatic gallbladder cancer: Results of the phase II GOCCHI study 2000–13. Proc Am Soc Clin Oncol 2003; 22: 273, abstract 1095
   Google Scholar
• Macdonald J., Smalley S., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New Engl J Med 2001; 345: 725–730
   PubMed Web of Science ®Google Scholar
• Cunningham D., Allum W., Stenning S. P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New Engl J Med 2006; 355: 11–20
   PubMed Web of Science ®Google Scholar
• Boige V., Pignon J. P., Saint-Aubert B., et al. Final results of a randomized trial comparing preoperative 5-fluorouracil / cisplatin to surgery alone in adenocarcinoma of the stomach and lower esophagus. J Clin Oncol 2007; 25: 4510, (supplement 18S)
   Google Scholar
• Tepper J., Krasna M., Niedwicki D., et al. Superiority of trimodality therapy to surgery alone in esophageal cancer: Results of CALGB 9781. J Clin Oncol 2006; 24: 4012, (supplement 18S)
   Google Scholar
• Stahl M., et al. Preoperative chemotherapy or radiochemotherapy in esophagogastric adenocarcinoma trial. J Clin Oncol 2007; 25: 4511, (supplement 18S)
   Google Scholar
• Bedenne L., Michel P., Bouche, et al. Chemo-radiation followed by surgery compared to chemo-radiation alone in locally advanced operable thoracic esophageal cancer: a randomized multicentric phase III trial (FFCD 9102). J Clin Oncol 2007; 25: 1160–1168
   PubMed Web of Science ®Google Scholar
• Wagner A. D., Grothe W., Haerting J., et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903–2909
   PubMed Web of Science ®Google Scholar
• Van Cutsem E., Moiseyenko V. M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991–4997
   PubMed Web of Science ®Google Scholar
• Andre T., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350(23)2343–2351
   PubMed Web of Science ®Google Scholar
• Tournigand C., et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer–a GERCOR study. J Clin Oncol 2006; 24(3)394–400
   PubMed Web of Science ®Google Scholar
• Argyriou A. A., et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 2006; 67(12)2253–2255
   PubMed Web of Science ®Google Scholar
• von Delius S., et al. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study. Invest New Drugs 2007; 25(2)173–180
   PubMed Web of Science ®Google Scholar
• Meininger V., et al. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5(2)107–117
   PubMed Web of Science ®Google Scholar
• Cassidy J., et al. Randomized double blind placebo controlled pahse III study assessing the efficacy of xaliproden in reducing the cumulative peripheral sensory neuropathy induced by the oxaliplatin and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients with metastatic colorectal cancer. Journal of Clinical Oncology 2006; 24(18s)3507
   Google Scholar
• Rich T., Gunderson L. L., Lew R., et al. Patterns of Recurrence of rectal cancer after potentially curative surgery. Cancer 1983; 52: 1317–1329
   PubMed Web of Science ®Google Scholar
• Mendenhall W. M., Million R. R., Pfaff W. W. Patterns of recurrence in adenocarcinoma of the rectum and rectosigmoid treated with surgery alone: Indications in treatment planning with adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 1983; 9: 977–985
   PubMed Web of Science ®Google Scholar
• Piliphen S. J., Heilweil M., Quan S. H., et al. Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer 1984; 53: 1354–1362
   PubMed Web of Science ®Google Scholar
• Gastrointestinal Tumor Study Group. Prolongation of the disease-free survival in surgically treated rectal carcinoma. N Engl J Med 1985; 312: 1465–1472
   PubMed Web of Science ®Google Scholar
• Krook J. E., Moertel C. G., Gunderson L. L., et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. New Engl J Med 1991; 324: 709–715
   PubMed Web of Science ®Google Scholar
• Wolmark N., Wieand S., Hyams D. M., et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiation for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 2000; 92: 388–396
   PubMed Web of Science ®Google Scholar
• Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731–1740
   PubMed Web of Science ®Google Scholar
• Dunst J., Reese T., Debus J., et al. Phase II study of preoperative chemoradiation with capecitabine in rectal cancer. Proc Am Soc Clin Oncol 2004; 22, 14S abstract 3559
   Web of Science ®Google Scholar
• Mohiuddin M., Winter K., Mitchell E., et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 2006; 24: 650–655
   PubMed Web of Science ®Google Scholar
• Ryan D. P., Niedzwiecki D., Hollis D., et al. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol 2006; 24: 2557–2562
   PubMed Web of Science ®Google Scholar
• Willett C. G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Medicine 2004; 110: 145–147
   Google Scholar
• Chung K. Y., Minsky D., Schrag E., et al. Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer. Proc Am Soc Clin Oncol 2006; 24: 18S, abstracts 3560
   Google Scholar